All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Olvi-Vec Plus Chemo Yields Disease Control in Platinum-Relapsed or -Refractory ES-SCLC

March 25th 2025

Olvi-vec plus chemotherapy led to disease control in extensive-stage small cell lung cancer that was relapsed/refractory to platinum chemotherapy.

Nivolumab Plus Sunitinib Hits Primary End Point in Advanced Bone Sarcoma IMMUNOSARC Study

March 25th 2025

Nivolumab plus sunitinib displayed early-phase efficacy in advanced bone sarcoma.

Targeted Treatment and Improved Radiation Technologies Offer Advantages in CRC Realm

March 25th 2025

Yufei Liu, MD, PhD, discusses current radiation strategies, including SBRT and IMRT, along with the benefits of radiation therapy in colorectal cancer.

Novel Curriculum Aims to Address Burnout and Foster Wellness Among Fellows

March 25th 2025

Thejal Srikumar, MD, MPH, discusses the Yale School of Medicine's unique approach to offering fellows a space to address professional burnout.

Reduced Radiotherapy Margins Yield Outcomes Comparable With Standard Margins in HGG

March 24th 2025

A randomized trial found no significant differences in recurrence or survival with smaller radiation margins vs standard RTOG protocols in patients with HGG.

Eribulin and Trabectedin Yield Comparable Real-World OS Outcomes in Advanced Liposarcoma

March 24th 2025

A real-world study showed OS outcomes with eribulin similar to those with trabectedin in doxorubicin-pretreated patients with advanced liposarcoma.

Divarasib Looks to Best Sotorasib/Adagrasib and Solidify a Role in KRAS G12C-Mutated NSCLC

March 24th 2025

Benjamin Herzberg, MD, details research in KRAS G12C-mutated NSCLC with divarasib and how he currently selects between available therapies in this space.

Moffitt Study Finds New Immunotherapy Strategy for Enhancing Melanoma Treatment

March 24th 2025

Moffitt Cancer Center researchers found a way to boost cancer immunotherapy by targeting a protein called macrophage receptor with collagenous structure.

EMA to Review Application for Expanded Indication for Sugemalimab in Unresectable NSCLC

March 24th 2025

A Type II variation application has been submitted to the EMA for the expanded approval of sugemalimab for unresectable stage III NSCLC.

NMPA Approves sNDA for Toripalimab Plus Bevacizumab in Advanced HCC

March 24th 2025

The combination of toripalimab and bevacizumab has been approved in China for the treatment of patients with unresectable or metastatic HCC.

Emerging Therapies in Myelofibrosis Could Extend Beyond JAK Inhibitors

March 24th 2025

Raajit Rampal, MD, PhD, discusses current JAK inhibitor treatment options for myelofibrosis and additional therapies being evaluated in clinical trials.

Chaos: Friend or Foe?

March 24th 2025

Jill Gilbert, MD, discusses professional strategy techniques that she has found useful through incredibly challenging times.

Enfortumab Vedotin Shows Manageable Safety in Older Patients With Urothelial Carcinoma

March 24th 2025

Enfortumab vedotin demonstrated a manageable safety profile and no unexpected toxicities in patients aged 80 years and older with urothelial carcinoma.

Five Under 5: Top Oncology Videos for the Week of 3/16

March 23rd 2025

The top 5 OncLive videos of the week cover insights in gynecologic cancer, multiple myeloma, urothelial cancer, MPNs, and prostate cancer.

Physical Functioning Measures May Predict Survival Outcomes, ICANS Risk With CAR T-Cell Therapy in NHL

March 23rd 2025

The risk of developing ICANS with CAR T-cell therapy was higher in patients with NHL who experienced a recent fall and could not balance on their left leg.

The OncFive: Top Oncology Articles for the Week of 3/16

March 22nd 2025

Pembrolizumab combination gets full approval in select HER2+ gastric/GEJ cancer, PSMA PET imaging agent is cleared for prostate cancer, and more from OncLive.

Residential-Specific Factors and ADT Use Influence HRQOL Outcomes in Bladder and Prostate Cancer

March 22nd 2025

Adjuvant HRQOL outcomes improved in patients with bladder cancer living in rural areas and were worse with ADT plus radiotherapy after prostatectomy.

Oncologists Call for Equity and Female Representation in Research During Women’s History Month

March 21st 2025

Shruti Patel, MD, highlights women making strides to improve cancer care and the need for equitable gender representation among oncology researchers.

Selection of Frontline CDK4/6 Inhibitors Hinges on Patient Health Status in HR+/HER2– Metastatic Breast Cancer

March 21st 2025

Tanya Gupta, MD, details FDA-approved CDK4/6 inhibitors and considerations for selecting treatment in HR-positive, HER2-negative metastatic breast cancer.

New Grant Funds First-of-Its-Kind Gene Therapy to Treat Aggressive Brain Cancer

March 21st 2025

The California Institute for Regenerative Medicine has awarded a $6 million grant to USC investigators pioneering a new genetic therapy to treat glioblastoma.